Current Treatment Options in Patients with Hepatitis C Virus Genotype 6

Nghia H Nguyen; Mindie H Nguyen

doi:10.1016/j.gtc.2015.07.010

Current Treatment Options in Patients with Hepatitis C Virus Genotype 6

Gastroenterol Clin North Am. 2015 Dec;44(4):871-81. doi: 10.1016/j.gtc.2015.07.010. Epub 2015 Aug 8.

Authors

Nghia H Nguyen¹, Mindie H Nguyen²

Affiliations

¹ School of Medicine, University of California, San Diego, La Jolla, CA, USA; Division of Gastroenterology and Hepatology, Stanford University Medical Center, Palo Alto, CA, USA.
² Liver Transplant Program, Division of Gastroenterology and Hepatology, Stanford University Medical Center, 750 Welch Road, #210, Palo Alto, CA 94304, USA. Electronic address: [email protected].

PMID: 26600225
DOI: 10.1016/j.gtc.2015.07.010

Abstract

Approximately 3% of the world's population is chronically infected with hepatitis C virus (HCV). In some southeast Asian countries the prevalence of HCV (∼6%-7%) far exceeds that seen in the United States (1.8%). The lesser known HCV genotype 6 (HCV-6) is also common in patients from southeast Asia and the surrounding regions. Most data on direct-acting antivirals (DAAs) to date have been derived from clinical trials conducted in Western countries, where HCV-6 is rare. The standard of care for patients with HCV-6 is still pegylated interferon and ribavirin. However, data are emerging for several DAA combinations.

Keywords: Direct-acting agents; Genotype 6; Hepatitis C; SVR; Treatment.

Publication types

Review

MeSH terms

Antiviral Agents / therapeutic use*
Drug Administration Schedule
Drug Resistance, Viral
Drug Therapy, Combination
Genotype*
Hepacivirus / genetics*
Hepatitis C, Chronic / drug therapy*
Hepatitis C, Chronic / virology
Humans
Treatment Outcome

Substances

Antiviral Agents